Vote ‘no’ on AstraZeneca’s CEO bonus, proxy firm says by Arlene Weintraub Tuesday, May 8, 2018 AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.
J&J, AbbVie tout Imbruvica data in the face of a new AZ threat by Carly Helfand Monday, December 11, 2017 J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.
